LabCorp's Monogram Acquisition Clears Antitrust Review

Jul 17, 2009

NEW YORK (GenomeWeb News) – Laboratory Corporation of America's $107 million acquisition of Monogram Biosciences has cleared US antitrust review, the clinical lab giant said today.

Under the deal announced last month, LabCorp will acquire all of the outstanding shares of Monogram in a cash offer of $4.55 per share for a total equity value of $106.7 million. The acquisition price represented a significant premium over Monogram's closing price of $1.68 on the Nasdaq the day before the acquisition was announced.

The tender offer is scheduled to expire at the end of the day on July 29, unless it is extended. The firms previously said that they hope to close the acquisition during the third quarter.

Filed under

pharmacogenomics

Laboratory Corporation of America

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.